doi:10.48130/targetome-0026-0039

[1]

Jacob S, Garg P, Wadiwala I, Yazji JH, Alomari M, et al. 2022. Strategies for expanding donors pool in heart transplantation. Reviews in Cardiovascular Medicine 23:285

doi: 10.31083/j.rcm2308285

[2]

Rega F, Lebreton G, Para M, Michel S, Schramm R, et al. 2024. Hypothermic oxygenated perfusion of the donor heart in heart transplantation: the short-term outcome from a randomised, controlled, open-label, multicentre clinical trial. The Lancet 404:670−682

doi: 10.1016/s0140-6736(24)01078-x

[3]

Kim DY, Kang M, Kim J, Choi D, Lee SJ. 2025. Machine perfusion across different donor pathways in heart transplantation: a systematic review and network meta-analysis. The Journal of Heart and Lung Transplantation 44:1920−1932

doi: 10.1016/j.healun.2025.08.013

[4]

Iyer A, Dhital K. 2020. Cardiac donation after circulatory death. Current Opinion in Organ Transplantation 25:241−247

doi: 10.1097/mot.0000000000000758

[5]

Guo BY, Wang W, Li CH, Chen X, Liu JP, et al. 2025. Current situation and progress of heart preservation technology. Practical Journal of Organ Transplantation (Electronic Version) 13:188−192 (in Chinese)

doi: 10.3969/j.issn.2095-5332.2025.02.017

[6]

Huang J. 2025. Report on the development of organ donation and transplantation in China (2024). China: Tsinghua University Press. 248 pp. www.tup.tsinghua.edu.cn/en/book_11428801.html

[7]

Schladt DP, Israni AK. 2024. OPTN/SRTR 2022 annual data report: introduction. American Journal of Transplantation 24:S10−S18

doi: 10.1016/j.ajt.2024.01.011

[8]

D'Alessandro DA, Wolfe SB, Osho AA, Drezek K, Prario MN, et al. 2022. Hemodynamic and clinical performance of hearts donated after circulatory death. Journal of the American College of Cardiology 80:1314−1326

doi: 10.1016/j.jacc.2022.07.024

[9]

Kosuri Y, Moroi MK, Bauer SJ, Campbell A, Adamo A, et al. 2026. Understanding donor heart preservation: cellular mechanisms and clinical outcomes. Perfusion 41:547−558

doi: 10.1177/02676591251377571

[10]

Alam AH, Lee CY, Kanwar MK, Moayedi Y, Bernhardt AM, et al. 2025. Current approaches to optimize the donor heart for transplantation. The Journal of Heart and Lung Transplantation 44:672−680

doi: 10.1016/j.healun.2024.12.001

[11]

Quinn PJ. 1985. A lipid-phase separation model of low-temperature damage to biological membranes. Cryobiology 22:128−146

doi: 10.1016/0011-2240(85)90167-1

[12]

Celik A, Lindstedt S, McGiffin DC, Suen JY, Fraser JF, et al. 2025. Revitalizing donor organs: the potential of mitochondrial transplantation in heart and lung transplantation. The Journal of Heart and Lung Transplantation 44:1648−1658

doi: 10.1016/j.healun.2025.07.002

[13]

Védère M, Faure E, Chouabe C, Augeul L, Cadot-Jet N, et al. 2025. Extended preservation of heart grafts: LYPS solution maintains cardiac function during 20-hour static cold storage. International Journal of Molecular Sciences 26:11170

doi: 10.3390/ijms262211170

[14]

Nadeev AP, Kliver VE, Volkov AM, Fomichev AV, Sirota DA, et al. 2024. Histological and ultrastructural analysis of biopsy specimens of donor heart under conditions of extended period of pharmaco-cold ischaemia. Arkhiv Patologii 86:33−41

doi: 10.17116/patol20248605133

[15]

Li S, Nordick KV, Elsenousi AE, Bhattacharya R, Kirby RP, et al. 2025. Warm-ischemia and cold storage induced modulation of ferroptosis observed in human hearts donated after circulatory death and brain death. American Journal of Physiology Heart and Circulatory Physiology 328:H923−H936

doi: 10.1152/ajpheart.00806.2024

[16]

Tanaka M, Mokhtari GK, Terry RD, Gunawan F, Balsam LB, et al. 2005. Prolonged cold ischemia in rat cardiac allografts promotes ischemia–reperfusion injury and the development of graft coronary artery disease in a linear fashion. The Journal of Heart and Lung Transplantation 24:1906−1914

doi: 10.1016/j.healun.2004.06.007

[17]

Lindsey ML, Brunt KR, Kirk JA, Kleinbongard P, Calvert JW, et al. 2021. Guidelines for in vivo mouse models of myocardial infarction. American Journal of Physiology: Heart and Circulatory Physiology 321:H1056−H1073

doi: 10.1152/ajpheart.00459.2021

[18]

Leivaditis V, Mulita F, Dahm M, Grapatsas K, Papatriantafyllou A, et al. 2024. History of the development of isolated heart perfusion experimental model and its pioneering role in understanding heart physiology. Archives of Medical Sciences Atherosclerotic Diseases 9:e109−e121

doi: 10.5114/amsad/188270

[19]

Martin JL, Costa ASH, Gruszczyk AV, Beach TE, Allen FM, et al. 2019. Succinate accumulation drives ischaemia-reperfusion injury during organ transplantation. Nature Metabolism 1:966−974

doi: 10.1038/s42255-019-0115-y

[20]

Bhatt DL, Lopes RD, Harrington RA. 2022. Diagnosis and treatment of acute coronary syndromes: a review. The Journal of the American Medical Association 327:662−675

doi: 10.1001/jama.2022.0358

[21]

Braunwald E. 2012. Unstable angina and non–ST elevation myocardial infarction. American Journal of Respiratory and Critical Care Medicine 185:924−932

doi: 10.1164/rccm.201109-1745CI

[22]

Otterspoor LC, van Nunen LX, Rosalina TT, Veer MV, Tuijl SV, et al. 2017. Intracoronary hypothermia for acute myocardial infarction in the isolated beating pig heart. American Journal of Translational Research 9:558−568

[23]

Arnold M, Do P, Davidson SM, Large SR, Helmer A, et al. 2024. Metabolic considerations in direct procurement and perfusion protocols with DCD heart transplantation. International Journal of Molecular Sciences 25:4153

doi: 10.3390/ijms25084153

[24]

Murphy E, Steenbergen C. 2008. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiological Reviews 88:581−609

doi: 10.1152/physrev.00024.2007

[25]

Jennings RB, Reimer KA. 1991. The cell biology of acute myocardial ischemia. Annual Review of Medicine 42:225−246

doi: 10.1146/annurev.me.42.020191.001301

[26]

Chouchani ET, Pell VR, Gaude E, Aksentijević D, Sundier SY, et al. 2014. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature 515:431−435

doi: 10.1038/nature13909

[27]

Milliken AS, Nadtochiy SM, Brookes PS. 2021. Abstract P311: blocking succinate release enhances mitochondrial reactive oxygen species generation and worsens ischemia-reperfusion injury. Circulation Research 129:AP311−AP311

doi: 10.1161/res.129.suppl_1.P311

[28]

Latchana N, Peck JR, Whitson B, Black SM. 2014. Preservation solutions for cardiac and pulmonary donor grafts: a review of the current literature. Journal of Thoracic Disease 6:1143−1149

doi: 10.3978/j.issn.2072-1439.2014.05.14

[29]

Pulis RP, Wu BM, Kneteman NM, Churchill TA. 2000. Conservation of phosphorylation state of cardiac phosphofructokinase during in vitro hypothermic hypoxia. American Journal of Physiology Heart and Circulatory Physiology 279:H2151−H2158

doi: 10.1152/ajpheart.2000.279.5.H2151

[30]

Li S, Nordick KV, Elsenousi AE, Hassan AM, Shaju RA, et al. 2026. Effect of cold storage solution on warm ischemia-induced myocardial plasma membrane damage and pyroptosis in human hearts from circulatory death donors. The Journal of Thoracic and Cardiovascular Surgery 171:439−453.e1

doi: 10.1016/j.jtcvs.2025.08.038

[31]

Folch-Puy E, Panisello A, Oliva J, Lopez A, Castro Benítez C, et al. 2016. Relevance of endoplasmic reticulum stress cell signaling in liver cold ischemia reperfusion injury. International Journal of Molecular Sciences 17:807

doi: 10.3390/ijms17060807

[32]

Kyösola K. 1981. Mitochondrial injury and autophagocytosis within the myocardial cell after the cold ischaemic anoxic asystole. Scandinavian Journal of Thoracic and Cardiovascular Surgery 15:83−85

doi: 10.3109/14017438109101028

[33]

Kohlhauer M, Pell VR, Burger N, Spiroski AM, Gruszczyk A, et al. 2019. Protection against cardiac ischemia-reperfusion injury by hypothermia and by inhibition of succinate accumulation and oxidation is additive. Basic Research in Cardiology 114:18

doi: 10.1007/s00395-019-0727-0

[34]

Jespersen NR, Hjortbak MV, Lassen TR, Støttrup NB, Johnsen J, et al. 2020. Cardioprotective effect of succinate dehydrogenase inhibition in rat hearts and human myocardium with and without diabetes mellitus. Scientific Reports 10:10344

doi: 10.1038/s41598-020-67247-4

[35]

Greene JG, Porter RHP, Eller RV, Greenamyre JT. 1993. Inhibition of succinate dehydrogenase by malonic acid produces an "excitotoxic" lesion in rat striatum. Journal of Neurochemistry 61:1151−1154

doi: 10.1111/j.1471-4159.1993.tb03634.x

[36]

Lampropoulou V, Sergushichev A, Bambouskova M, Nair S, Vincent EE, et al. 2016. Itaconate links inhibition of succinate dehydrogenase with macrophage metabolic remodeling and regulation of inflammation. Cell Metabolism 24:158−166

doi: 10.1016/j.cmet.2016.06.004

[37]

Ashrafian H, Czibik G, Bellahcene M, Aksentijević D, Smith AC, et al. 2012. Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway. Cell Metabolism 15:361−371

doi: 10.1016/j.cmet.2012.01.017

[38]

Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, et al. 2012. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. The New England Journal of Medicine 367:1098−1107

doi: 10.1056/NEJMoa1114287

[39]

Parker AM, Lees JG, Tate M, Phang RJ, Velagic A, et al. 2025. MitoQ protects against oxidative stress-induced mitochondrial dysregulation in human cardiomyocytes. Journal of Molecular and Cellular Cardiology Plus 13:100469

doi: 10.1016/j.jmccpl.2025.100469

[40]

Mokhtari B, Delkhah M, Badalzadeh R, Ghaffari S. 2025. Mitochondrial transplantation combined with mitoquinone and melatonin: a survival strategy against myocardial reperfusion injury in aged rats. Experimental Physiology 110:844−856

doi: 10.1113/ep092292

[41]

Zielonka J, Joseph J, Sikora A, Hardy M, Ouari O, et al. 2017. Mitochondria-targeted triphenylphosphonium-based compounds: syntheses, mechanisms of action, and therapeutic and diagnostic applications. Chemical Reviews 117:10043−10120

doi: 10.1021/acs.chemrev.7b00042

[42]

Turkseven S, Bolognesi M, Brocca A, Pesce P, Angeli P, et al. 2020. Mitochondria-targeted antioxidant mitoquinone attenuates liver inflammation and fibrosis in cirrhotic rats. American Journal of Physiology Gastrointestinal and Liver Physiology 318:G298−G304

doi: 10.1152/ajpgi.00135.2019

[43]

Szeto HH. 2014. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology 171:2029−2050

doi: 10.1111/bph.12461

[44]

Dai DF, Hsieh EJ, Chen T, Menendez LG, Basisty NB, et al. 2013. Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides. Circulation Heart Failure 6:1067−1076

doi: 10.1161/circheartfailure.113.000406

[45]

Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, et al. 2018. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology 90:e1212−e1221

doi: 10.1212/wnl.0000000000005255

[46]

Daubert MA, Yow E, Dunn G, Marchev S, Barnhart H, et al. 2017. Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide. Circulation Heart Failure 10:e004389

doi: 10.1161/circheartfailure.117.004389

[47]

Fosgerau K, Hoffmann T. 2015. Peptide therapeutics: current status and future directions. Drug Discovery Today 20:122−128

doi: 10.1016/j.drudis.2014.10.003

[48]

Liu CX, Guo XY, Zhou YB, Wang H. 2024. Therapeutic role of Chinese medicine targeting Nrf2/HO-1 signaling pathway in myocardial ischemia/reperfusion injury. Chinese Journal of Integrative Medicine 30:949−960

doi: 10.1007/s11655-024-3657-0

[49]

Zheng Z, Xu J, Mao Y, Mei Z, Zhu J, et al. 2024. Sulforaphane improves post-resuscitation myocardial dysfunction by inhibiting cardiomyocytes ferroptosis via the Nrf2/IRF1/GPX4 pathway. Biomedicine & Pharmacotherapy 179:117408

doi: 10.1016/j.biopha.2024.117408

[50]

Mangla B, Javed S, Sultan MH, Kumar P, Kohli K, et al. 2021. Sulforaphane: a review of its therapeutic potentials, advances in its nanodelivery, recent patents, and clinical trials. Phytotherapy Research 35:5440−5458

doi: 10.1002/ptr.7176

[51]

Li Q, Xiang Y, Chen Y, Tang Y, Zhang Y. 2018. Ginsenoside Rg1 protects cardiomyocytes against hypoxia/reoxygenation injury via activation of Nrf2/HO-1 signaling and inhibition of JNK. Cellular Physiology and Biochemistry 44:21−37

doi: 10.1159/000484578

[52]

Liu R, Lin Z, Yang F, Duan JK. 2023. Mechanisms of ginsenoside Rg1 in protecting cardiomyocytes by Sestrin2. Journal of Kunming Medical University 44:19−25

doi: 10.12259/j.issn.2095-610X.S20230614

[53]

Wang Q, Wei L, Chen G, Chen Q. 2025. Ginsenoside Rg1 in Parkinson's disease: from basic research to clinical applications. Frontiers in Pharmacology 16:1490480

doi: 10.3389/fphar.2025.1490480

[54]

Du B, Fu Q, Yang Q, Yang Y, Li R, et al. 2025. Different types of cell death and their interactions in myocardial ischemia–reperfusion injury. Cell Death Discovery 11:87

doi: 10.1038/s41420-025-02372-5

[55]

Sun W, Chi T, Chen X, Li Z. 2021. HO-1 participate in the protection of RES in rat heart suffered from hypothermic preservation. Advances in Clinical and Experimental Medicine 30:147−152

doi: 10.17219/acem/130607

[56]

Berman AY, Motechin RA, Wiesenfeld MY, Holz MK. 2017. The therapeutic potential of resveratrol: a review of clinical trials. npj Precision Oncology 1:35

doi: 10.1038/s41698-017-0038-6

[57]

Aliabadi-Zuckermann AZ, Moayedifar R, Zuckermann AO. 2026. Ferroptosis blockade during machine perfusion: a new lever for donation after circulatory death heart transplantation? Transplantation 110:e532−e534

doi: 10.1097/tp.0000000000005615

[58]

Yuan Y, Huang H, Hu T, Zou C, Qiao Y, et al. 2024. Curcumin pretreatment attenuates myocardial ischemia/reperfusion injury by inhibiting ferroptosis, autophagy and apoptosis via HES1. International Journal of Molecular Medicine 54:110

doi: 10.3892/ijmm.2024.5434

[59]

Li T, Jin J, Pu F, Bai Y, Chen Y, et al. 2023. Cardioprotective effects of curcumin against myocardial I/R injury: a systematic review and meta-analysis of preclinical and clinical studies. Frontiers in Pharmacology 14:1111459

doi: 10.3389/fphar.2023.1111459

[60]

Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. 2007. Bioavailability of curcumin: problems and promises. Molecular Pharmaceutics 4:807−818

doi: 10.1021/mp700113r

[61]

Lei I, Huang W, Noly PE, Naik S, Ghali M, et al. 2023. Metabolic reprogramming by immune-responsive gene 1 up-regulation improves donor heart preservation and function. Science Translational Medicine 15:eade3782

doi: 10.1126/scitranslmed.ade3782

[62]

Perucca E. 2002. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16:695−714

doi: 10.2165/00023210-200216100-00004

[63]

Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, et al. 2011. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. The Lancet Neurology 10:609−617

doi: 10.1016/s1474-4422(11)70107-7

[64]

Zimmerman HJ, Ishak KG. 1982. Valproate-induced hepatic injury: analyses of 23 fatal cases. Hepatology 2:591S−597S

doi: 10.1002/hep.1840020513

[65]

Welt FGP, Batchelor W, Spears JR, Penna C, Pagliaro P, et al. 2024. Reperfusion injury in patients with acute myocardial infarction: JACC scientific statement. Journal of the American College of Cardiology 83:2196−2213

doi: 10.1016/j.jacc.2024.02.056

[66]

Zhang X, Du Q, Yang Y, Wang J, Dou S, et al. 2017. The protective effect of Luteolin on myocardial ischemia/reperfusion (I/R) injury through TLR4/NF-κB/NLRP3 inflammasome pathway. Biomedicine & Pharmacotherapy 91:1042−1052

doi: 10.1016/j.biopha.2017.05.033

[67]

Yan Q, Li Y, Yan J, Zhao Y, Liu Y, et al. 2018. Effects of luteolin on regulatory proteins and enzymes for myocyte calcium circulation in hypothermic preserved rat heart. Experimental and Therapeutic Medicine 15:1433−1441

doi: 10.3892/etm.2017.5514

[68]

Taliou A, Zintzaras E, Lykouras L, Francis K. 2013. An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. Clinical Therapeutics 35:592−602

doi: 10.1016/j.clinthera.2013.04.006

[69]

He W, Xu J, Li X. 2026. Macrophage polarization in inflammatory regulation: molecular mechanisms, therapeutic targets, and translational challenges. Cellular and Molecular Life Sciences 83:164

doi: 10.1007/s00018-025-06041-9

[70]

Qu D, Han J, Ren H, Yang W, Zhang X, et al. 2016. Cardioprotective effects of astragalin against myocardial ischemia/reperfusion injury in isolated rat heart. Oxidative Medicine and Cellular Longevity 2016:8194690

doi: 10.1155/2016/8194690

[71]

Knosalla C, Stegmann A. 2026. Targeting mitochondrial vulnerability during prolonged cold ischemia. Transplantation 110:e975−e976

doi: 10.1097/tp.0000000000005669

[72]

Mendoza A, Patel P, Robichaux D, Ramirez D, Karch J. 2024. Inhibition of the mPTP and lipid peroxidation is additively protective against I/R injury. Circulation Research 134:1292−1305

doi: 10.1161/circresaha.123.323882

[73]

Shanmuganathan S, Hausenloy DJ, Duchen MR, Yellon DM. 2005. Mitochondrial permeability transition pore as a target for cardioprotection in the human heart. American Journal of Physiology Heart and Circulatory Physiology 289:H237−H242

doi: 10.1152/ajpheart.01192.2004

[74]

Deng KQ, Xu Z, Wang Q, Cai HH, Fan D, et al. 2026. Inhibition of annexin A2 facilitates PHB2-mediated mitophagy in cardiomyocytes to alleviate cardiac injury and remodeling after infarction. Circulation 153:826−844

doi: 10.1161/circulationaha.125.077780

[75]

Kayejo VG, Fellner H, Thapa R, Keyel PA. 2023. Translational implications of targeting annexin A2: from membrane repair to muscular dystrophy, cardiovascular disease and cancer. Clinical and Translational Discovery 3:e240

doi: 10.1002/ctd2.240

[76]

Prislusky MI, Lam JGT, Contreras VR, Ng M, Chamberlain M, et al. 2024. The septin cytoskeleton is required for plasma membrane repair. EMBO Reports 25:11

doi: 10.1038/s44319-024-00195-6

[77]

Li DW, Li JH, Wang YD, Li GR. 2015. Atorvastatin protects endothelial colony-forming cells against H₂O₂-induced oxidative damage by regulating the expression of annexin A2. Molecular Medicine Reports 12:7941−7948

doi: 10.3892/mmr.2015.4440

[78]

Varyukhina S, Lamazière A, Delaunay JL, de Wreede A, Ayala-Sanmartin J. 2022. The Ca²⁺- and phospholipid-binding protein Annexin A2 is able to increase and decrease plasma membrane order. Biochimica et Biophysica Acta (BBA) - Biomembranes 1864:183810

doi: 10.1016/j.bbamem.2021.183810

[79]

Zhang Y, Wang Y, Li J, Li C, Liu W, et al. 2023. Annexin A2 facilitates neovascularization to protect against myocardial infarction injury via interacting with macrophage Yap and endothelial integrin β3. Shock 60:573−584

doi: 10.1097/shk.0000000000002198

[80]

Bergonzini M, Loreni F, Lio A, Russo M, Saitto G, et al. 2023. Panoramic on epigenetics in coronary artery disease and the approach of personalized medicine. Biomedicines 11:2864.

doi: 10.3390/biomedicines11102864

[81]

Zhang LX, Zhao Y, Cheng G, Guo TL, Chin YE, et al. 2010. Targeted deletion of NF-kappaB p50 diminishes the cardioprotection of histone deacetylase inhibition. American Journal of Physiology-Heart and Circulatory Physiology 298:H2154−H2163

doi: 10.1152/ajpheart.01015.2009

[82]

Pickell Z, Williams AM, Alam HB, Hsu CH. 2020. Histone deacetylase inhibitors: a novel strategy for neuroprotection and cardioprotection following ischemia/reperfusion injury. Journal of the American Heart Association 9:e016349

doi: 10.1161/jaha.120.016349

[83]

Ren D, Wang X, Ha T, Liu L, Kalbfleisch J, et al. 2013. SR-A deficiency reduces myocardial ischemia/reperfusion injury; involvement of increased microRNA-125b expression in macrophages. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1832:336−346

doi: 10.1016/j.bbadis.2012.10.012

[84]

Yang Q, Yang K, Li A, Tan W. 2013. Anti-apoptosis and expression of microRNA-21 in rat myocardium during early ischemia-reperfusion injury. Journal of Central South University Medical Sciences 38:483−489 (in Chinese)

doi: 10.3969/j.issn.1672-7347.2013.05.007

[85]

Hartung T, Smirnova L, Platz S, Amelio I, Leist M. 2025. The need for epigenotoxicity testing. ALTEX – Alternatives to Animal Experimentation 42:565−590

doi: 10.14573/altex.2509281

[86]

Jackson AL, Linsley PS. 2010. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nature Reviews Drug Discovery 9:57−67

doi: 10.1038/nrd3010

[87]

Kabłak-Ziembicka A, Badacz R, Okarski M, Wawak M, Przewłocki T, et al. 2023. Cardiac microRNAs: diagnostic and therapeutic potential. Archives of Medical Science 19:1360−1381

doi: 10.5114/aoms/169775

[88]

Xu T, Dai J, Li Y, Zhou J, Zhao Y, et al. 2025. NPBS Atlas: a comprehensive data resource for exploring the biological sources of natural products. Journal of Cheminformatics 17:172

doi: 10.1186/s13321-025-01116-y

[89]

Chen Y, Rosenkranz C, Hirte S, Kirchmair J. 2022. Ring systems in natural products: structural diversity, physicochemical properties, and coverage by synthetic compounds. Natural Product Reports 39:1544−1556

doi: 10.1039/d2np00001f

[90]

Al-Shuhaib MBS, Al-Shuhaib JMB. 2025. Assessing therapeutic value and side effects of key botanical compounds for optimized medical treatments. Chemistry & Biodiversity 22:e202401754

doi: 10.1002/cbdv.202401754

[91]

Ma J, Wang X, Sun Q. 2026. Beyond cytotoxicity: molecular mechanisms of natural products as multi-targeting modulators and chemo-sensitizers in oncology. Frontiers in Pharmacology 17:1782874

doi: 10.3389/fphar.2026.1782874

[92]

Wong ZW, Thanikachalam PV, Ramamurthy S. 2017. Molecular understanding of the protective role of natural products on isoproterenol-induced myocardial infarction: a review. Biomedicine & Pharmacotherapy 94:1145−1166

doi: 10.1016/j.biopha.2017.08.009

[93]

Jiang M, Ni J, Cao Y, Xing X, Wu Q, et al. 2019. Astragaloside IV attenuates myocardial ischemia-reperfusion injury from oxidative stress by regulating succinate, lysophospholipid metabolism, and ROS scavenging system. Oxidative Medicine and Cellular Longevity 2019:9137654

doi: 10.1155/2019/9137654

[94]

Luo Y, Lu S, Dong X, Xu L, Sun G, et al. 2017. Dihydromyricetin protects human umbilical vein endothelial cells from injury through ERK and Akt mediated Nrf2/HO-1 signaling pathway. Apoptosis 22:1013−1024

doi: 10.1007/s10495-017-1381-3

[95]

Shen M, Wu RX, Zhao L, Li J, Guo HT, et al. 2012. Resveratrol attenuates ischemia/reperfusion injury in neonatal cardiomyocytes and its underlying mechanism. PLoS One 7:e51223

doi: 10.1371/journal.pone.0051223

[96]

Huang Q, Yao Y, Wang Y, Li J, Chen J, et al. 2024. Ginsenoside Rb2 inhibits p300-mediated SF3A2 acetylation at lysine 10 to promote Fscn1 alternative splicing against myocardial ischemic/reperfusion injury. Journal of Advanced Research 65:365−379

doi: 10.1016/j.jare.2023.12.012

[97]

Lin S, Chai Z, Zeng H, Yang B, Chi J, et al. 2024. Atranones and dolabellanes with cardiomyocyte protective activity against cold ischemic injury from a coral-associated fungus Stachybotrys chartarum. Phytochemistry 225:114199

doi: 10.1016/j.phytochem.2024.114199

[98]

Lin S, Zeng H, Wang C, Chai Z, Zhang X, et al. 2024. Discovery of novel natural cardiomyocyte protectants from a toxigenic fungus Stachybotrys chartarum. Bioorganic Chemistry 148:107461

doi: 10.1016/j.bioorg.2024.107461

[99]

Jin X, Chi J, Zhao Y, Jiang R, Wei J, et al. 2023. Indoloquinazoline alkaloids with cardiomyocyte protective activity against cold ischemic injury from Aspergillus clavatonanicus. Bioorganic Chemistry 135:106482

doi: 10.1016/j.bioorg.2023.106482

[100]

Thi Duy Ngoc N, Yurchenko EA, Thi Hoai Trinh P, Menchinskaya ES, Thi Dieu TV, et al. 2025. Secondary metabolites of Vietnamese marine fungus Penicillium chermesinum 2104NT-1.3 and their cardioprotective activity. Regional Studies in Marine Science 81:104003

doi: 10.1016/j.rsma.2024.104003

[101]

Asong-Fontem N, Panisello-Rosello A, Lopez A, Imai K, Zal F, et al. 2021. A novel oxygen carrier (M101) attenuates ischemia-reperfusion injuries during static cold storage in steatotic livers. International Journal of Molecular Sciences 22:8542

doi: 10.3390/ijms22168542

[102]

Mittal A, Kumar N, Chauhan NS. 2019. Curcumin encapsulated PEGylated nanoliposomes: a potential anti-infective therapeutic agent. Indian Journal of Microbiology 59:336−343

doi: 10.1007/s12088-019-00811-3

[103]

Wang WY, Cao YX, Zhou X, Wei B. 2019. Delivery of folic acid-modified liposomal curcumin for targeted cervical carcinoma therapy. Drug Design, Development and Therapy 13:2205−2213

doi: 10.2147/dddt.S205787

[104]

Yuan Y, Yu L, Bi C, Huang L, Su B, et al. 2025. A new paradigm for drug discovery in the treatment of complex diseases: drug discovery and optimization. Chinese Medicine 20:40

doi: 10.1186/s13020-025-01075-4

[105]

Mikropoulou EV, Basdeki A, Halabalaki M. 2026. Metabolism and bioavailability aspects of natural products of plant origin using mass spectrometry-based and metabolomic approaches. Natural Product Reports 43:1130−1180

doi: 10.1039/d5np00022j

[106]

Kim HK, Kim SJ, Gil WJ, Yang CS. 2025. Exploring the therapeutic potential of phytochemicals: challenges and strategies for clinical translation. Phytomedicine 145:157090

doi: 10.1016/j.phymed.2025.157090

[107]

Hu Z, Ye Y, Zhang Y. 2021. Large-scale culture as a complementary and practical method for discovering natural products with novel skeletons. Natural Product Reports 38:1775−1793

doi: 10.1039/d0np00069h

[108]

Tian DS, Zhang X, Cox RJ. 2025. Comparing total chemical synthesis and total biosynthesis routes to fungal specialized metabolites. Natural Product Reports 42:720−738

doi: 10.1039/d4np00015c

[109]

Mendiola Pla M, Bowles DE. 2024. Delivery of therapeutics to solid organs using ex vivo machine perfusion. In Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays, eds Hock FJ, Pugsley MK. Cham: Springer. pp. 1791–1810 doi: 10.1007/978-3-031-35529-5_102

[110]

Schneider C, Gordon ON, Edwards RL, Luis PB. 2015. Degradation of curcumin: from mechanism to biological implications. Journal of Agricultural and Food Chemistry 63:7606−7614

doi: 10.1021/acs.jafc.5b00244

[111]

Yanamadala Y, Muthumula CMR, Khare S, Gokulan K. 2025. Strategies to enhance nanocrystal formulations for overcoming physiological barriers across diverse routes of administration. International Journal of Nanomedicine 20:367−402

doi: 10.2147/ijn.S494224

[112]

Bertin S, Haefliger D, Schneider AG, Giraud R, Perez MH, et al. 2025. Effects of extracorporeal membrane oxygenation circuits on drug sequestration: a review of ex vivo experiments. Journal of Clinical Medicine 14:8060

doi: 10.3390/jcm14228060

[113]

Alamán-Díez P, García-Gareta E, Napal PF, Arruebo M, Pérez MÁ. 2022. In vitro hydrolytic degradation of polyester-based scaffolds under static and dynamic conditions in a customized perfusion bioreactor. Materials 15:2572

doi: 10.3390/ma15072572

[114]

Nykänen AI, Keshavjee S, Liu M. 2024. Creating superior lungs for transplantation with next-generation gene therapy during ex vivo lung perfusion. The Journal of Heart and Lung Transplantation 43:838−848

doi: 10.1016/j.healun.2024.01.016

[115]

Wang F, Lucchinetti E, Lou PH, Hatami S, Chakravarty A, et al. 2024. Optimizing resuscitation of the donation after circulatory death heart by mitochondrial protection in a female porcine model. Anesthesiology 141:524−540

doi: 10.1097/aln.0000000000005093

[116]

Mondal NK, Li S, Elsenousi AE, Mattar A, Nordick KV, et al. 2024. NADPH oxidase overexpression and mitochondrial OxPhos impairment are more profound in human hearts donated after circulatory death than brain death. American Journal of Physiology Heart and Circulatory Physiology 326:H548−H562

doi: 10.1152/ajpheart.00616.2023

[117]

Kim CK, Mukadam S, Agrawal DK. 2025. Differential effects of brain death and circulatory death on myocardial integrity and transplant outcomes. Journal of Surgery and Research 8:416−435

doi: 10.26502/jsr.10020466